Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02640053 | Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome | completed | N/A | 46 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 |
| clinicaltrials |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04094896 | TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer | unknown | Phase 2 | 200 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04095390 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer(INPHASE) | unknown | Phase 2 | 60 | Jinming YuOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | terminated | Phase 2 | 64 | Women's Cancer Study Group GmbHOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03797248 | Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer | unknown | — | 310 | Chang Gung Memorial HospitalOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT04088110 | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | unknown | Phase 2 | 77 | Fuzhou General HospitalOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01815476 | The Prone Breast Radiation Therapy Trial | completed | N/A | 378 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01153672 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | completed | N/A | 8 | University of WashingtonOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02248662 | Impact of Radiation Therapy on Breast Conservation in DCIS | completed | — | 3,436 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02816164 | A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia(REaCT-G2) | completed | Phase 4 | 324 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03247478 | Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure(CTREP) | completed | — | 160 | Peking UniversityOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01975363 | Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer | completed | N/A | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03609671 | Emotions Immunology and Breast Cancer | completed | N/A | 17 | Luz A. Venta, MDOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03523299 | Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 21, 2019 | clinicaltrials |
| NCT04003558 | Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01) | unknown | — | 1,500 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | suspended | Phase 3 | 375 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00513695 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 68 | University of WashingtonOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04046159 | Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ | unknown | Phase 3 | 810 | National Taiwan University HospitalOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT02216136 | Tumor: Breast Ratio Study(T:B) | completed | — | 162 | Washington University School of MedicineOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT04034823 | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer | unknown | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 26, 2019 | clinicaltrials |
| NCT04033172 | Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )(Pyrotinib) | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT02806817 | ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism | completed | Early Phase 1 | 40 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT04021069 | Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer | unknown | — | 800 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | terminated | Early Phase 1 | 4 | University of California, San DiegoOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT04011085 | Tw HER2 Positive Breast Cancer Productivity & Utility Study | unknown | — | 300 | Taiwan Epidemiology AssociationOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02611544 | Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | completed | N/A | 91 | Indiana UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02370277 | Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer | completed | — | 36 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01434303 | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | May 20, 2019 | clinicaltrials |
| NCT02587663 | Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI | completed | N/A | 300 | University of Southern CaliforniaOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT02908178 | Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ | completed | — | 28,291 | Yale UniversityOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT03947242 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. | unknown | N/A | 48 | Henan Cancer HospitalOTHER_GOV | 0 | May 15, 2019 | clinicaltrials |
| NCT03886389 | Breast Cancer Diet Intervention Study(BCDIS) | completed | N/A | 80 | Helse Stavanger HFOTHER_GOV | 0 | May 13, 2019 | clinicaltrials |
| NCT02817607 | Study to Assess Breast Sensation Before and After Breast Cancer Treatment | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | unknown | Phase 2 | 184 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | PfizerINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03919253 | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | unknown | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 0 | Apr 18, 2019 | clinicaltrials |
| NCT03910712 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC(Pyrotinib) | unknown | Phase 2 | 250 | Peking Union Medical College HospitalOTHER | 0 | Apr 10, 2019 | clinicaltrials |
| NCT03908749 | A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2 | unknown | — | 300 | Anhui Provincial HospitalOTHER_GOV | 0 | Apr 9, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
| NCT02610920 | Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection | withdrawn | Early Phase 1 | 0 | Columbia UniversityOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02923037 | Hatha Yoga in Breast Cancer Survivors | terminated | N/A | 27 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2019source: clinicaltrials